LIVE Key Note Presentations @Biotech Week Boston, October 5, 2016 Boston Convention and Exhibition Center | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« LIVE – Afternoon Session added – Gene Therapy Development & Cell Therapy Bioprocessing – Overcoming Scientific and Development Challenges @Biotech Week Boston, October 5, 2016 Boston Convention and Exhibition Center

FEBS Journal Special Issue on CRISPR/Cas9 Gene Editing by news.wiley.com »

LIVE Key Note Presentations @Biotech Week Boston, October 5, 2016 Boston Convention and Exhibition Center

October 5, 2016 by 2012pharmaceutical

LIVE Key Note Presentations @Biotech Week Boston, October 5, 2016 3:25PM

Boston Convention and Exhibition Center

#BiotechWeekBoston

avivalev-ari@alum.berkeley.edu

@pharma_BI

@AVIVA1950

ANNOUNCEMENT

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

will cover in REAL TIME

Biotech Week Boston, October 5, 2016 @ Boston Convention and Exhibition Center

In Attendance, streaming LIVE using Social Media

Aviva Lev-Ari, PhD, RN

Editor-in-Chief

http://pharmaceuticalintelligence.com

Key Sessions

Arnold I. Caplan, Ph.D.

Adult Mesenchymal Stem Cells: The New Medicine

Case Western Reserve University

HSC – hematopoietic Stem Cells
MSC – mesengenic in vitro not in Tissue Engineering – can be derived from multiple tissue sources

all MSC are Pericytes cells on capillaries and microvessels – CD34 CD146
during injury – pericyte – differentiates – sentinal fro damage and innate tissue regenerations, sense environment
MSC = Medicinal Signaling Cell – the injury specific – 655 Clinical Trials – KIDNEY AND OTHER ORGAN TRANSPLANTATION
hCAP-18/LL37 is secreted by hMSCs
LL37 is in Maternal milk and prevent infection in neonatals
Lipoaspirate
immunomodulatory and Trophic activity
Universal Stem Cell Niche pMSC, Niche
MSCs in cancer metastasis: BRCA, prostate and Melanoma (binding protein) – pericyte pull
http://www.ctte

David DiGiusto, Ph.D.

Building a Sustainable Academic Engine for Feeding De-Risked Assets into the Biopharma Pipeline

Stanford Health Care / Stanford School of Medicine, Cell and Gene Medicine

viral vector
bacterial culture
standard tissue

Risks of developing Academic Cell Therapy Products
Center for Definitive and Curative Medicine – Regenerative Medicine

translational Staging Score: min 6 points
Scientific Review and Prioritization: 0-9 points

Lentiviral vector mediated FOXP3 converts T effector cells into T regulatory cells – CD4 LV-FOXP3
CD34 CD90+ blood stem cells: ADM of alpha CD117mAB 0 transplant HSC
Cancer Immunotherapy: CD19/CD@@: Leukemia
cell transduction
Vector Production
Plasmid Production
Skin DEBnb- low keratinocyte stem cells – neoantigen
COmbining CRISPR/Cas9 and rAAV6 mediates High Targeting Efficiencies into peripheral blood CD34+ +HSPCs

Cutting: mRNA and RNP
recombination – AAV only, mRNA : Total population vs Sorted GFP(high) – get 95% due to Gene correction
Genome editing:

starting DNA
Edited DNA
Edited Protein

4. Closed systems, scalable technology, reagents and automation, clean reagents

5. Invest in the Delivery Channel: Basic Research, Product development, clinical research

6. Transplantation Blood and marrow

7. Cell pharmacy

8. Translational Research : Funding Mix Commercialization, licensing and commercial

9. Infrastructure utilized by every stage of development is different

Posted in BioTechnology - Venture Creation, Conference Coverage with Social Media, Regenerative Biology and Medicine | Leave a Comment

Leave a ReplyCancel reply

%d